Raj Kannan is a seasoned biopharmaceutical executive with over three decades of global leadership experience across the biotech and pharmaceutical industries. He has successfully built and scaled high-performing teams and organizations, led major product launches across cardio-vascular, respiratory, and rare diseases, and created significant value through strategic M&A and operational execution.

Raj most recently served as Chief Executive Officer of I-Mab, a global biotech company focused on immuno-oncology, where he led the company through a period of transformation and strategic prioritization. Prior to I-Mab, he was CEO of Aerie Pharmaceuticals, where he oversaw the company’s acquisition by Alcon, and Chiasma, Inc., where he guided the company through a successful commercial launch and eventual merger with Amryt Pharma.

Raj held key leadership roles at Boehringer-Ingelheim and at Merck KgAA. Raj holds a Bachelor of Science in Chemistry and an MBA in Marketing.